What empiric inpatient antibiotic regimen is recommended for an adult hospitalized with community‑acquired pneumonia who has no severe penicillin allergy or high‑risk comorbidities?

Empiric Inpatient Antibiotic Regimen for Community-Acquired Pneumonia

For adults hospitalized with community-acquired pneumonia on a medical ward (non-ICU) without severe penicillin allergy or high-risk comorbidities, use either a respiratory fluoroquinolone alone (levofloxacin 750 mg IV daily, moxifloxacin 400 mg IV daily) OR a β-lactam (ceftriaxone 1g IV daily, cefotaxime 1g IV q8h, or ampicillin 1g IV q6h) plus a macrolide (azithromycin 500 mg IV daily). 1

Algorithmic Approach to Treatment Selection

Step 1: Confirm Non-ICU Status

• Patient is hemodynamically stable
• No need for vasopressors or mechanical ventilation
• No severe sepsis or septic shock

Step 2: Choose Between Two Equally Effective Regimens

Option A: Respiratory Fluoroquinolone Monotherapy (Strong recommendation, Level I evidence) 1

• Levofloxacin 750 mg IV daily
• Moxifloxacin 400 mg IV daily
• Gemifloxacin 320 mg daily (if oral tolerated)

Option B: β-lactam + Macrolide Combination (Strong recommendation, Level I evidence) 1

• Preferred β-lactams:
  • Ceftriaxone 1g IV q24h
  • Cefotaxime 1g IV q8h
  • Ampicillin 1g IV q6h
• Plus macrolide:
  • Azithromycin 500 mg IV daily (Level II evidence for ICU, extrapolated to ward)
  • Clarithromycin 500 mg IV q12h
  • Erythromycin 1g IV q6h

Step 3: Special Considerations

If recent antibiotic use within 90 days:

• Choose the regimen from a different antibiotic class than previously used 2, 1

If gram-negative risk factors present (aspiration, structural lung disease, nursing home):

• Consider ertapenem 1g IV daily as the β-lactam 1

For penicillin allergy:

• Use respiratory fluoroquinolone monotherapy 1
• If fluoroquinolone contraindicated: respiratory fluoroquinolone + aztreonam 1

Key Evidence Supporting These Recommendations

The 2007 IDSA/ATS guidelines provide the most authoritative recommendations for non-ICU hospitalized CAP, with both regimens receiving strong recommendations based on Level I evidence 1. These recommendations have been validated across multiple studies and remain the standard of care.

Important distinction from recent updates: The 2019 ATS/IDSA guidelines 3 and 2025 updates 4, 5 primarily address outpatient therapy and severe CAP, but do not fundamentally change the non-ICU inpatient recommendations established in 2007.

Critical Pitfalls to Avoid

Do not use macrolide monotherapy for hospitalized patients—resistance rates make this inadequate 1. Macrolides must be combined with a β-lactam if not using fluoroquinolone monotherapy.

Do not delay first antibiotic dose—administer while still in the emergency department 1. This improves mortality outcomes.

Do not continue IV therapy unnecessarily—switch to oral when patient is hemodynamically stable, improving clinically, and able to take oral medications (typically within 48-72 hours) 1.

Duration of Therapy

Treat for minimum 5 days, with patient afebrile for 48-72 hours and no more than one CAP-associated sign of clinical instability before discontinuation 1. Recent evidence supports shorter courses (minimum 3 days) in patients reaching clinical stability 4, though the 5-day minimum remains the established guideline recommendation.

Transition to Oral Therapy

Switch from IV to oral when:

• Hemodynamically stable
• Clinically improving
• Able to ingest medications
• Functioning GI tract

Oral equivalents:

• Levofloxacin 750 mg daily
• Moxifloxacin 400 mg daily
• Amoxicillin 1g TID (if susceptible pathogen identified)
• Azithromycin 500 mg daily